VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2021 | ESMO 2021 highlights in colorectal cancer

Claudia Cardone • 19 Sep 2021
ESMO 2021
Colorectal Cancer Adagrasib Atezolizumab Bevacizumab Cetuximab FOLFOXIRI Ipilimumab Nivolumab Temozolomide
AtezoTRIBE KRYSTAL-1 MAYA Immuno-Oncology

Claudia Cardone, MD, Istituto Nazionale Tumori-IRCCS Fondazione “G. Pascale”, Naples, Italy, discusses her highlights from the European Society for Medical Oncology (ESMO) 2021 Congress, including the AtezoTRIBE trial (NCT03721653), the MAYA trial (NCT03832621), and the KRYSTAL-1 trial (NCT03785249). This interview took place at the ESMO 2021 Congress.

More from Claudia Cardone

0:59
Improvements for women in oncology
Claudia Cardone • 19 Sep 2021
0:48
Benefits of social media in oncology
Claudia Cardone • 19 Sep 2021
1:40
ESMO: Young Oncologists Track
Claudia Cardone • 19 Sep 2021

Related Videos

1:20
A promising future for drug development in gastrointestinal cancer
Hani Babiker
1:43
Cemiplimab prospects: CRC, CSCC & HNSCC
Hani Babiker
4:05
PLATO and immunotherapy trials in anal cancer
David Sebag-Montefiore
4:47
Regorafenib + nivolumab in MMR proficient advanced CRC
Richard D. Kim

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals